Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Exclusion Criteria

• •Have had another primary malignancy within the previous 3 years (with the exception of carcinoma in situ of the breast, cervix, or localized prostate cancer and non-melanoma skin cancer that has been adequately treated)
• •Have received prior cell transfer therapy that included a nonmyeloablative or myeloablative chemotherapy regimen
• •Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or pathway-targeting agents
• •Chemotherapy or radiotherapy with projected completion within 4 weeks of initiating study treatment
• •Bisphosphonate therapy for symptomatic hypercalcemia
• •Have had treatment with systemic immunostimulatory agents (including, but not limited to, interferon \[IFN\]-alpha or interleukin \[IL\]-2) within 6 weeks before initiation of study treatment
• •Active or prior documented autoimmune or inflammatory disorders
• •Subjects who have any form of human immondeficiency virus (HIV)infection
• •Have severe infections within 4 weeks before initiation of study treatment
• •Have received a live or attenuated vaccine within 28 days of the non-myeloablative lymphodepletion (NMA-LD regimen)
• •Subjects with a history of hypersensitivity reaction(s) to any component of the LN-145 therapy and/or the other study drugs
• •* Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) \>= 450 msec for males (and \>= 470 msec for females) calculated from 3 electrocardiograms (ECGs) (within a 30-minute timeframe) or history of familiar long-QT syndrome
• •Subjects who have a left ventricular ejection fraction (LVEF) \< 45% or who are New York Heart Association functional classification class II or higher
• •Serious illnesses or medical conditions, which would pose increased risk for study participation and/or compliance with the protocol
• •Known clinically significant liver disease
• •Have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of =\< 60%
• •Subjects with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases
• •Subjects who are pregnant or breastfeeding
• •Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or human immunodeficiency virus
• •Treatment with any other investigational agent within 4 weeks before initiation of study treatment